caretrace.iopowered by▸healthparse
SearchCohort Builder
Tools▾
KOL FinderTerritoriesDrug Compare
AI Query
Browse▾
By stateBy specialty
Pricing
SearchCohort BuilderToolsKOL FinderTerritoriesDrug CompareAI QueryBrowseBy stateBy specialtyPricing
PROVIDER PROFILE · NPI 1891731667

Nikolai PodoltsevM.D., PH.D.

Medical OncologyNew Haven, CTI
CROSS-REFERENCE

Related data on other Healthparse brands

ProviderScore
OIG/SAM exclusion screening, sanctions history
© 2026 CareTrace
PricingContactPrivacyTerms
MEDICARE UTILIZATION · PART B · 2024
Total beneficiaries
237
Unique beneficiaries
—
Total services
473
Distinct HCPCS
7
Medicare payment
$34K
Peer benchmark
Q1
Q2
Q3
Q4
Q5
Total Medicare services vs. 71 Medical Oncology providers in CT — above median (cohort median 459).
REFERRAL NETWORK

Where Nikolai Podoltsev's patients come from & go

Directional shared-patient flow from Medicare claims — who sends patients to this provider (inbound) and where this provider's patients go next (outbound). 15 inbound referrers · 0 outbound destinations.

Receives referrals from
Inbound — who sends patients here
PhysicianPatientsVisits
YALE NEW HAVEN HOSPITAL76342
Lisa Barbarotta
Nurse Practitioner · New Haven, CT
431,189
Yale University
Clinical Laboratory · New Haven, CT
40222
NASH, IRWIN30109
MILLER, CINDY25142
American Medical Response Of Connecticut Incorporated
Ambulance Service Provider · New Haven, CT
2383
Richard Torres
Pathology · New Haven, CT
22100
Quest Diagnostics Llc
Clinical Laboratory · Wallingford, CT
1992
Amer Zeidan
Medical Oncology · New Haven, CT
19349
Irena Tocino
Diagnostic Radiology · New Haven, CT
16124
Lisa Rivera
Nurse Practitioner · New Haven, CT
15152
Terri Parker
Hematology · New Haven, CT
14141
Refers patients to
Outbound — where patients go next
No outbound pairs above the suppression threshold.
Source: CMS Physician Shared Patient Patterns (30-day window, Medicare FFS). Direction = a beneficiary seen by the first provider, then the second, within 30 days; a proxy for referral, not a documented referral. Pairs with fewer than 11 shared beneficiaries are suppressed.
PRESCRIBING · PART D · 2024
Total Rx claims
564
Beneficiaries
—
Total drug cost
$7.1M
Distinct drugs
20
Brand share
74.3%
Top prescribed drugs
Ruxolitinib Phosphate132 claims
Hydroxyurea49 claims
Bosutinib45 claims
Imatinib Mesylate40 claims
Ondansetron38 claims
QUALITY · MIPS · 2024
Final MIPS score
87.4
Quality
77.4
Cost
74.3
Improvement activities
40.0
Promoting interop.
100.0
Payment adjustment
0.52%
Group
INDUSTRY PAYMENTS · OPEN PAYMENTS · 2024
Total received
$15K
Payment records
25
By payment type
Consulting Fee$11K
Travel and Lodging$3K
Food and Beverage$1K